Key Highlights

● Genmab shares climbed roughly 28.3% after positive Phase 3 trial results.

● The trial met its endpoints in head and neck cancer patients.

● Reported data showed about a 50% reduction in the risk of death.

● Major US indexes closed modestly higher on October 28 amid heavy earnings activity.

Genmab A/S (ADR) (NASDAQ:GMAB), the Danish biotechnology company, was one of the clearest clinical-driven winners of the October 28, 2026 US session, climbing roughly 28.3% in regular trading. The catalyst was a late-stage trial readout: a Phase 3 study in head and neck cancer met its endpoints, with results reported to show approximately a 50% reduction in the risk of death. For a company whose value rests substantially on the clinical success of its pipeline, a positive pivotal trial is among the most powerful catalysts available, and the market responded accordingly.

Why a Pivotal Trial Carries Weight

The confirmed driver carries real weight. A Phase 3 trial is the final and most rigorous stage of clinical testing before a therapy can be submitted for regulatory approval, and meeting the study's endpoints is the outcome on which the entire program hinges. The reported magnitude of benefit is what makes this result especially notable: a roughly 50% reduction in the risk of death is a large effect in oncology, where incremental gains are often hard-won. In head and neck cancer, a setting with meaningful unmet need, a result of that scale has the potential to reshape expectations for the drug's commercial opportunity and its standing against existing options.

Sizing a Binary Event

A single-session gain of about 28.3% in a company the size of Genmab reflects how binary late-stage clinical events can be for biotechnology valuations. Positive pivotal data remove a major source of uncertainty in one stroke, and investors move quickly to price in the improved probability that the therapy advances toward regulatory filing and eventual use. The move captures both the fact that the trial succeeded and the strength of the reported effect, which together argue for a more valuable program than the market had been crediting before the readout.

What's Confirmed

Precision about the confirmed facts matters here. What is established is that a Phase 3 head and neck cancer trial met its endpoints and that the reported benefit was on the order of a 50% reduction in the risk of death. The specific therapy and regimen, the trial's patient population and comparator, secondary endpoint details, safety data, the timing of any regulatory submission, and partnership economics are not part of the confirmed driver and are not asserted here. The stock's reaction should be read as the market's response to a successful pivotal trial with a large reported effect, not as a verdict on details that have not been independently confirmed.

Session Backdrop

The broader market provided a supportive but secondary backdrop. US stocks closed modestly higher on October 28 after a weak open, with the S&P 500 up about 0.3% near 7,744, the Dow up roughly 0.2%, and the Nasdaq Composite higher by about 0.3%. It was an exceptionally heavy earnings day, and breadth was neutral-to-mixed, with six of eleven S&P sectors finishing lower. Leadership came from AI-infrastructure and semiconductor names, with the Philadelphia Semiconductor Index up 1.75%, a dynamic largely disconnected from a clinical-stage oncology story like Genmab's.

Clinical News Overwhelms the Rate Backdrop

The macro environment leaned higher-for-longer. The Federal Reserve held its policy rate at 3.75%–4.00% in a 10–2 vote, with two governors dissenting in favor of a quarter-point hike, and the statement pointed to activity expanding at a strong pace with inflation still elevated. The 10-year Treasury yield rose to around 5.03%. Higher rates generally weigh on long-duration biotechnology valuations by increasing the discount applied to distant cash flows, which makes Genmab's advance a clear case of company-specific, clinical news overwhelming an otherwise unfavorable rate backdrop. On a day dominated by earnings, a positive Phase 3 result was enough to send the shares sharply higher.